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Akt substrate TBC1D1 regulates GLUT1 expression through the mTOR
pathway in 3T3-L1 adipocytes
Qiong L. ZHOU1, Zhen Y. JIANG1, John HOLIK, Anil CHAWLA, G. Nana HAGAN, John LESZYK and Michael P. CZECH2
Programme in Molecular Medicine, University of Massachusetts Medical School, 373 Plantation Street, Worcester, MA 01605, U.S.A.
Multiple studies have suggested that the protein kinase Akt/PKB
(protein kinase B) is required for insulin-stimulated glucose
transport in skeletal muscle and adipose cells. In an attempt to
understand links between Akt activation and glucose transport
regulation, we applied mass spectrometry-based proteomics and
bioinformatics approaches to identify potential Akt substrates
containing the phospho-Akt substrate motif RXRXXpS/T. The
present study describes the identification of the Rab GAP
(GTPase-activating protein)-domain containing protein TBC1D1
[TBC (Tre-2/Bub2/Cdc16) domain family, member 1], which is
closely related to TBC1D4 [TBC domain family, member 4, also
denoted AS160 (Akt substrate of 160 kDa)], as an Akt substrate
that is phosphorylated at Thr590. RNAi (RNA interference)-me-
diated silencing of TBC1D1 elevated basal deoxyglucose uptake
by approx. 61% in 3T3-L1 mouse embryo adipocytes, while
the suppression of TBC1D4 and RapGAP220 under the same
conditions had little effect on basal and insulin-stimulated deoxy-
glucose uptake. Silencing of TBC1D1 strongly increased expres-
sion of the GLUT1 glucose transporter but not GLUT4 in cultured
adipocytes, whereas the decrease in TBC1D4 had no effect.
Remarkably, loss of TBC1D1 in 3T3-L1 adipocytes activated the
mTOR (mammalian target of rapamycin)-p70 S6 protein kinase
pathway, and the increase in GLUT1 expression in the cells treated
with TBC1D1 siRNA (small interfering RNA) was blocked by
the mTOR inhibitor rapamycin. Furthermore, overexpression
of the mutant TBC1D1-T590A, lacking the putative Akt/PKB
phosphorylation site, inhibited insulin stimulation of p70 S6
kinase phosphorylation at Thr389, a phosphorylation induced by
mTOR. Taken together, our data suggest that TBC1D1 may be
involved in controlling GLUT1 glucose transporter expression
through the mTOR-p70 S6 kinase pathway.
Key words: Akt substrate of 160 kDa (AS160), GLUT1,
GTPase-activating protein (GAP), insulin signalling, mammalian
target of rapamycin (mTOR), protein kinase B (PKB)/Akt.
INTRODUCTION
Akt/PKB (protein kinase B) is a key intermediate in signalling
pathways initiated by hormones and growth factors that activate
PI3K (phosphoinositide 3-kinase) [1–4]. Three Akt/PKB isoforms
are phosphorylated and activated by two upstream protein
kinases in response to the formation of PtdIns(3,4,5)P3. Of these
upstream kinases, one is PDK1 (phosphoinositide-dependent
protein kinase 1) [1–4], while the other is mTOR (mammalian
target of rapamycin) in complex with the protein rictor [5].
Numerous studies have demonstrated that activation of Akt/PKB
is involved in insulin’s metabolic and mitogenic functions
including the regulation of gene expression, glucose transport,
glycogen synthesis, protein synthesis, cell survival and cell
growth [1–4]. Activated Akt/PKB regulates cellular functions
through phosphorylation of serine and threonine residues in the
motif RXRXXS/T of downstream target proteins [6–8]. Multiple
Akt/PKB substrates have been discovered, such as transcription
factor FOXO (forkhead box O) proteins [9–12], the pro-apopto-
tic factor Bad [13], IκB (inhibitory κB) kinase [14,15], the mito-
genic factor Raf1 [16–18], the p53 negative regulator Mdm2
[17,18], the cyclin-dependent kinase inhibitors p27kip1 [19–
21] and p21cip1 [22], endothelial nitric oxide synthase [23,24],
glycogen synthase kinase-3 [25], WNK1 (protein kinase with
no lysine 1) [26,27] and the GAPs (GTPase-activating proteins)
tuberous sclerosis complex TSC2 (tuberous sclerosis complex 2)
[28,29], AS160 (Akt substrate of 160 kDa) [30] and many others
[31,32].
Previously, proteins with GAP domains and activity have been
identified as Akt/PKB substrates [33]. For example, the RabGAP
TBC1D4 [TBC (Tre-2/Bub2/Cdc16) domain family, member 4;
also known as AS160] was discovered by Lienhard and co-
workers as an Akt/PKB substrate in adipocytes that further work
showed has a role in part of the signalling cascade that mediates
GLUT4 glucose transporter translocation to the plasma membrane
[34–36]. Another example is TSC2, a specific GAP for the small
GTPase Rheb [37–39]. Akt phosphorylates TSC2 at Thr1462 and
inhibits its GAP activity [28,29,40], leading to the activation
of the Rheb GTPase and subsequent activation of the protein
kinase mTOR by a mechanism not yet clearly defined [41–
43]. It is well established that mTOR activates protein synthesis
through the activation of p70 S6 kinase and regulation of the
eIF4F [eIF (eukaryotic initiation factor) 4F] complex [44,45].
In this pathway, mTOR phosphorylates the Thr389 residue in the
hydrophobic motif of the p70 S6 kinase and activates the kinase
[46–48]. In turn, p70 S6 kinase subsequently activates the S6
protein of the 40S ribosomal subunit by phosphorylating multiple
residues including Ser235, Ser236, Ser240 and Ser244, which leads to
Abbreviations used: AS160, Akt substrate of 160 kDa; CHO-T cell, Chinese hamster ovary cell transfected with the human insulin receptor; 4E-BP1,
eukaryotic initiation factor 4E-binding protein 1; eIF, eukaryotic initiation factor; FOXO, forkhead box O; GAP, GTPase-activating protein; GLUT, glucose
transporter; HA, haemagglutinin; KRH, Krebs-ringer Hepes; MALDI–TOF, matrix-assisted laser-desorption ionization–time-of-flight; mTOR, mammalian
target of rapamycin; PAS, phospho-Akt/PKB substrate; PI3K, phosphoinositide 3-kinase; PKB, protein kinase B; PTB domain, phosphotyrosine-binding
domain; RNAi, RNA interference; siRNA, small interfering RNA; RT–PCR, reverse transcription–PCR; TBC, Tre-2/Bub2/Cdc16; TBC1D1, TBC domain family,
member 1; TBC1D4, TBC domain family, member 4; TSC, tuberous sclerosis complex; WNK1, protein kinase with no lysine 1; WT, wild-type.
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an increase in mRNA translation [49]. Active p70 S6 kinase also
stimulates translation by phosphorylating several other substrates
involved in protein synthesis such as eIF4B, eEF2K (eukaryotic
elongation factor 2-kinase) and SKAR (S6 kinase 1 Aly/REF-like
target) [50]. In addition, mTOR induces hyperphosphorylation of
4E-BP1 (eIF4E-binding protein 1) and disrupts the binding of 4E-
BP1 to eIF4E, which in turn mediates the binding of eIF4F, a
large protein complex, to the 5′ cap structure of mRNAs [51–53].
Thus, Akt-mediated activation of the mTOR pathway increases
the translation of specific mRNA subpopulations.
It is likely that other unknown Akt/PKB effectors may
be involved in insulin-induced protein synthesis and glucose
transport. To search for such new Akt/PKB substrates, we applied
an MS-based proteomics approach to identify potential candidates
enriched by immunoprecipitation with a polyclonal antibody
against the PAS (phospho-Akt/PKB substrate) motif RXRXXpS/
T [27,54]. We also applied the web-based motif searching program
Scansite (http://www.scansite.mit.edu) [8] to search for proteins
that are expressed in adipocytes and contain sequences with high
similarity to known Akt/PKB phosphorylation sites. In the present
study, we identified TBC1D1 (TBC domain family, member 1) as
a potential Akt/PKB substrate in insulin-stimulated 3T3-L1 adipo-
cytes. TBC1D1 is phosphorylated at Thr590 within a highly conser-
ved Akt/PKB motif (RRRANT) in cultured adipocytes treated
with insulin. Functional analysis revealed that RNAi (RNA inter-
ference)-mediated gene silencing of TBC1D1 activates the
mTOR-p70 S6 kinase pathway, induces protein expression of the
glucose transporter GLUT1 and increases basal glucose transport
in adipocytes. These data suggest that the Akt/PKB substrate
TBC1D1 may be a negative regulatory element in the insulin
signalling pathway of mTOR that regulates GLUT1 protein
expression.
EXPERIMENTAL
Materials
Human insulin was obtained from Eli Lilly. Monoclonal antibody
against HA (haemagglutinin) epitope 6E2, and rabbit polyclonal
antibodies against phospho-Akt/PKB Ser473, phospho-Erk1/2,
phospho-S6 ribosomal protein (Ser235/236), phospho-p70 S6 kinase
(Thr389), S6 ribosomal protein and phosphorylated Akt/PKB
substrate motif were from Cell Signalling Technology. Rabbit
polyclonal antibody against Myc epitope was from Upstate
Biotechnology. Monoclonal antibody against GLUT4 was
from Biogenesis. Rabbit polyclonal antibody against GLUT1
was kindly provided by Dr Paul Pilch (Boston University
School of Medicine, Boston, MA, U.S.A.). Rabbit polyclonal
antibody against non-muscle myosin IIB was from Covance.
Chicken polyclonal antibody against mouse TBC1D4 C-terminus
(HPTNDKAKAGNKP) was generated by Quality Controlled
Biochemicals, Hopkinton, MA, U.S.A.
Cell culture and electroporation of 3T3-L1 adipocytes
The 3T3-L1 fibroblasts were grown in DMEM (Dulbecco’s
modified Eagle’s medium) supplemented with 10% FBS (fetal
bovine serum), 50 µg/ml streptomycin and 50 units/ml penicillin,
and differentiated into adipocytes as described [55,56]. The 3T3-
L1 adipocytes were transfected with siRNA (small interfering
RNA) duplexes or cDNA expression constructs by electroporation
as described [56]. Briefly, the adipocytes, on the fourth day of
differentiation, were detached from culture dishes with 0.25%
trypsin and 0.5 mg of collagenase/ml in PBS, washed twice and
resuspended in PBS. Half of the cells from one 150-mm-diameter
dish were then mixed with the indicated siRNA-duplexes or
siRNA smart pools, which were delivered to the cells by a pulse
of electroporation with a Bio-Rad gene pulser II system at the
setting of 0.18 kV and 950 µF capacitance. After electroporation,
cells were immediately mixed with fresh media and reseeded into
multiple-well plates, designated for Western blotting, RT–PCR
(reverse transcription–PCR) or deoxyglucose uptake assay.
siRNAs and constructs
siRNA smart pools and duplexes were synthesized and purified by
Dharmacon Research and transfected into the 3T3-L1 fibroblasts
and adipocytes by electroporation as described previously
[56]. The targeting sequences of each gene are as follows:
Akt1/PKBα, AACCAGGACCACGAGAAGCUG; Akt2/PKBβ,
GAGAGGACCUUCCAUGUAG and UGCCAUUCUACAAC-
CAGGA. The smart pool siRNAs were used to induce
gene-specific silencing of TBC1D1 (M-040360), TBC1D4
(M-040174) and RapGAP220 (M-040315). cDNA expression
constructs: cDNAs encoding full-length mouse mKIAA1108
(gi 28972621) and human KIAA0603 (gi 3043729), provided
by Kazusa DNA Research Institute, Laboratory for Genome
Informatics (Kisarazu, Chiba, Japan), were used to construct full-
length TBC1D1 with a Myc epitope fused at the N-terminus
(Myc-TBC1D1 WT) and full-length TBC1D4 (AS160) with
an HA epitope tag at the N-terminus (HA-TBC1D4 WT),
respectively. The mutation Myc-TBC1D1-T590A was made by
the PCR-based site-directed mutagenesis.
RT–PCR and real-time PCR analysis of mRNA
Briefly, total RNA was extracted from cells that had been
transfected with siRNA using TRIZOL Reagent (Invitrogen).
Total RNA was measured by a spectrophotometer and, for RT–
PCR, 1 µg of total RNA was used in a cDNA reaction (Invitrogen).
PCR was performed on one-tenth of the total cDNA reaction
using specific primers of gene(s) of interest and a low number
of cycles (<25). The reactions were run on a gel and percentage
of knockdown was estimated by intensity of ethidium bromide-
stained bands as compared with scrambled siRNA controls. PCR
primers: mouse TBC1D1 forward primer: TCCTTTTGCTC-
TGAGGGCATC; reverse primer: TGTGGTCAAGTGCTTCT-
GGAGTTC. RapGAP220 forward primer: TGTGAATAACAT-
CCAGTCGCCG; reverse primer: CAGCAGCAGTGATAAAG-
TCCCC. For quantitative mRNA analysis, 1 µg of total RNA
from each sample was used for RT using iScript cDNA
Synthesis kit (Bio-Rad). An aliquot (10%) of each RT
reaction was subjected to quantitative real-time PCR analysis
using an iQ SYBR green supermix kit and Real-Time PCR
detection system following the manufacturers’ instructions
(MyiQ, Bio-Rad). We designed specific primers using the
database PrimerBank (http://pga.mgh.harvard.edu/primerbank).
HPRT (hypoxanthine–guanine phosphoribosyltransferase) was
used as standard housekeeping gene. Relative gene expression
was calculated by subtracting the Ct (threshold cycle number)
of the target genes from the Ct value of HPRT and squaring
this difference (i.e. difference2). Real-time PCR primers used
were: TBC1D1 forward primer, GAGCCAACACCCTGAGT-
CATT; and reverse primer, GGATTCAAAGTCCTTGCGTTCA.
GLUT1 forward primer, CAGTTCGGCTATAACACTGGTG;
and reverse primer, GCCCCCGACAGAGAAGATG. GLUT4
forward primer, GTGACTGGAACACTGGTCCTA; and reverse
primer, CCAGCCACGTTGCATTGTAG.
Immunoprecipitation and immunoblotting
After experimental treatments, the cells were solubilized in ice-
cold lysis buffer containing 50 mM Hepes (pH 7.4), 5 mM sodium
c© The Authors Journal compilation c© 2008 Biochemical Society
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pyrophosphate, 5 mM β-glycerophosphate, 10 mM sodium
fluoride, 2 mM EDTA, 2 mM Na3VO4, 1 mM PMSF, 10 µg/ml
aprotinin, 10 µg/ml leupeptin and 1% Triton X-100. Total cell
lysates of 1–2 mg of protein were immunoprecipitated with
antibodies against phospho-Akt/PKB substrates (1:100 dilution,
Cell Signalling), Myc epitope (9E10) or HA epitope (6E2) for 2 h
followed by incubation with 80 µl of Protein A–Sepharose 6MB
for 2 h at 4 ◦C. The beads were then washed four times with lysis
buffer before boiling for 5 min in Laemmli buffer.
To detect phospho-Akt/PKB substrates, phospho-Ser473
Akt/PKB, phospho-Thr389 p70 S6 kinase, phospho-Thr202/Tyr204
Erk1/2 and phospho-Ser234/236 S6 ribosomal protein, total cell
lysates (20 to 50 µg of protein) were resolved with SDS/PAGE
and electro-transferred to nitrocellulose membranes, which were
incubated with rabbit polyclonal anti-phospho-specific antibodies
(1:1000 dilution) overnight at 4 ◦C. Primary chicken antibody
against mouse TBC1D4 antibody (1 µg/ml), rabbit polyclonal
antibodies against total Akt/PKB (1:1000 dilution), GLUT1
(1:10000) and p70 S6 ribosomal protein (1:1000), and mouse
monoclonal antibodies against Myc epitope (1:1000), HA epitope
(1:1000) and GLUT4 (1:1000) were used to detect their antigens
using 20 to 50 mg of proteins from total cell lysates. All the
membranes were then incubated with appropriate horseradish
peroxidase-linked secondary antibodies (1:10000 dilution each)
for 1 h at room temperature (21 ◦C). The membranes were washed
with wash buffer (PBS, pH 7.4, 0.1% Tween 20) for 1 h at room
temperature after incubation with each antibody before detection
with ECL® (enhanced chemiluminescence) kit.
MS
Proteins immunoprecipitated with PAS antibody were resolved
on SDS/PAGE (5–15% gradient gel) and visualized with a
Silver-plus kit according to the procedure recommended by the
manufacturer (Bio-Rad). The protein bands were excised from
the silver-stained gel and digested with sequencing grade porcine-
modified trypsin (Promega). The tryptic peptides were analysed
by MALDI–TOF (matrix-assisted laser-desorption ionization–
time-of-flight) mass spectrometry as described previously [27].
The peptide mass spectrum was acquired over the range 500–
3500 Da. Peptide mass mapping was carried out against the NCBI
(National Center for Biotechnology Information) database using
the MS-FIT program (University of California, San Francisco,
CA, U.S.A.; http://prospector.ucsf.edu). To verify further the MS-
FIT identification, selected peptides were fragmented via PSD
(post-source decay) and searched against the NCBI database using
the MSTag program.
Deoxyglucose uptake assay
To detect the effect of specific gene silencing on insulin-
stimulated glucose transport, [3H]deoxyglucose uptake assays
were carried out in 3T3-L1 adipocytes as described previously
[17]. Briefly, siRNA-transfected cells were reseeded on 24-well
plates and cultured for 72 h before serum starvation for 3 h
with KRH (Krebs-ringer Hepes) buffer (130 mM NaCl, 5 mM
KCl, 1.3 mM CaCl2, 1.3 mM MgSO4, 25 mM Hepes, pH 7.4)
supplemented with 0.5% BSA and 2 mM sodium pyruvate.
Cells were then stimulated with insulin for 30 min at 37 ◦C.
Glucose uptake was initiated by addition of [1,2-3H]2-deoxy-
D-glucose to a final assay concentration of 100 µM for 5 min
at 37 ◦C. Assays were terminated by four washes with ice-cold
KRH buffer and the cells were solubilized with 0.4 ml of 1%
Triton X-100, and radioactivity was determined by scintillation
counting. Non-specific deoxyglucose uptake was measured in the
Figure 1 RabGAP domain-containing proteins, TBC1D1 and TBC1D4, are
Akt substrates
(A) Serum-starved 3T3-L1 adipocytes were treated with or without 100 nM wortmannin (WM)
for 20 min followed by incubation with or without 100 nM insulin (Ins) for 15 min. Total cell
lysate (6 mg of protein) was used for immunoprecipitation with PAS antibody as described in
the Experimental section. Protein bands on SDS/PAGE (5–15 % gel) were blotted with PAS
andibody and visualized by silver staining. The protein bands were excised and digested
in the gel with trypsin and the tryptic peptides were analysed with a MALDI-TOF mass
spectrometer. The identified proteins are indicated. (B) Schematic diagram of mouse TBC1D1,
TBC1D4 and RapGAP220. The domains predicted by the Pfam program and potential Akt/PKB
phosphorylation sites are shown. (C and D) Akt/PKB phosphorylates WT TBC1D1 and TBC1D4,
but not TBC1D1-T590A. 3T3-L1 adipocytes were transfected with Myc-tagged TBC1D1 WT and
TBC1D1-T590A. Con, control. (C) Myc-tagged proteins were immunoprecipitated (IP) from the
indicated cell lysates with anti-Myc polyclonal antibody (αMyc). Samples were then resolved
by SDS/PAGE and immunoblotted with anti-PAS antibody (αPAS). The anti-Myc (αMyc) blot
is also shown as control. (D) 3T3-L1 adipocyte lysates were immunoprecipitated (IP) with
anti-PAS antibody (αPAS) and samples were resolved by SDS/PAGE and immunoblotted
with anti-TBC1D4 antibody. Data are representative of three independent experiments.
presence of 20 µM cytochalasin B and was subtracted from each
determination to obtain specific uptake.
RESULTS
Insulin stimulates phosphorylation of multiple GAPs detected
by PAS antibodies
Many studies have reported that PAS antibodies recognize the
phosphorylated Akt/PKB substrate motif RXRXXpS/T in target
proteins of the kinase [27,30,54]. To identify new Akt/PKB
substrates, total cell lysates from control and insulin-stimulated
3T3-L1 adipocytes were immunoprecipitated with PAS antibody
and separated by SDS/PAGE, followed by silver staining.
Protein bands were excised and subjected to in-gel trypsin
digestion. The peptides produced were analysed by MALDI-
TOF MS. As shown in Figure 1(A), immunoprecipitation with
PAS antibodies enriched several phosphoproteins detectable
by Western blotting with PAS antibodies and silver staining
from insulin-stimulated cells. From these silver-stained protein
bands, we identified several Akt substrates such as WNK1
c© The Authors Journal compilation c© 2008 Biochemical Society
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and FOXO1 [18]. Interestingly, we also detected several
GAPs, including known Akt substrates TBC1D4 (AS160),
TSC2 and a 220 kDa RapGAP domain-containing protein
(RapGAP220, GeneID: 381383). An online Scansite motif search
(http://scansite.mit.edu) revealed that all of these GAPs contain
high-stringency Akt substrate motifs as shown in Figure 1(B).
To examine whether TBC1D4 is phosphorylated in insulin-
stimulated adipocytes, a chicken polyclonal antibody against
the mouse C-terminal peptide of TBC1D4 was produced. Using
anti-PAS antibodies for immunoprecipitation and anti-TBC1D4
antibody for Western blotting, we observed that insulin stimulated
TBC1D4 phosphorylation in adipocytes, whereas the PI3K
inhibitor wortmannin inhibited insulin’s effect (Figure 1D). Our
data confirm the initial previous report that TBC1D4 (AS160) is
an Akt substrate in insulin-stimulated 3T3-L1 adipocytes [30].
TBC GAP domain-containing protein TBC1D1 is a novel
Akt/PKB substrate
To identify additional potential Akt substrates, we scanned Akt
motifs with TBC GAP domain-containing proteins expressed
in differentiated 3T3-L1 adipocytes, based on microarray gene
profiling data (not shown). Interestingly, we found that the
Rab GAP TBC1D1 is expressed in the adipocytes and contains
several potential Akt motifs (Figure 1B). Similar to TBC1D4,
TBC1D1 contains one TBC GAP domain at the C-terminus,
two PTB domains (phosphotyrosine-binding domains) at the N-
terminus and four potential Akt substrate motifs, with Thr590
revealed as the highest stringency site according to the Scansite
motif search. To examine whether insulin stimulates TBC1D1
phosphorylation at this potential Akt site, the adipocytes were
transfected with expression vectors encoding either full-length
Myc-tagged WT (wild-type) mouse TBC1D1 or the Myc-tagged
TBC1D1-T590A mutant. Adipocytes were serum starved 48 h
after transfection, then stimulated or not with insulin (100 nM)
for 15 min; the cells were lysed and anti-Myc epitope antibody
was used to immunoprecipitate Myc-tagged TBC1D1-WT or
TBC1D1-T590A mutant proteins for Western blotting with
anti-PAS antibody. As shown in Figure 1(C), WT TBC1D1
was significantly phosphorylated in adipocytes incubated with
insulin, as detected by anti-PAS. However, insulin-stimulated
phosphorylation was not observed in the cells expressing the
TBC1D1-T590A mutant, suggesting that the Thr590 residue is
a unique Akt phosphorylation site on TBC1D1 in cultured
adipocytes treated with insulin.
RNAi-induced gene-specific silencing of TBC1D1 increases glucose
transport in 3T3-L1 adipocytes
It was reported that Akt-mediated phosphorylation of TBC1D4
is involved in the regulation of insulin-stimulated glucose
transporter Glut4 translocation and glucose transport in adipo-
cytes [34–36]. To test whether the novel Akt substrates TBC1D1
and RapGAP220 are required for the process of glucose transport,
these proteins were knocked down by RNAi-induced gene-
specific silencing. Interestingly, siRNA induced knockdown of
TBC1D1 mRNA by approx. 70% (Figures 2B and 2C), which
increased deoxyglucose transport by approx. 61% and 30% in
cultured adipocytes in the basal and low-dose (1 nM) insulin-
stimulated states respectively, as compared with cells treated
with scrambled siRNA (Figure 2A). However, no significant
difference was observed between glucose transporter activities
in the adipocytes transfected with the scrambled and TBC1D1
siRNAs when a maximal dose of insulin (100 nM) was used
to stimulate the cells. Surprisingly, we consistently observed
that the siRNA-induced silencing of TBC1D4 (AS160), by
80% at the protein level (as determined by Western blotting
with AS160 antibody, Figure 2D), had no effect on basal or
insulin-stimulated deoxyglucose transport in 3T3-L1 adipocytes
(Figure 2A). Similarly, suppression of the RapGAP220 mRNA as
indicated by RT–PCR (Figure 2E) did not alter either the basal or
insulin-stimulated deoxyglucose transport.
TBC1D1 functions in the regulation of GLUT1 protein expression
To address the question whether the increase in deoxyglucose
transport in the cultured adipocytes with TBC1D1 knockdown is
due to changes in the expression levels of glucose transporters,
we examined mRNA and protein levels of GLUT1 and GLUT4.
As shown in Figures 3(A) and 3(B), loss of TBC1D1 significantly
increased GLUT1 protein levels by about 40%, but did not alter
GLUT4 or Akt protein levels as detected by Western blotting,
when compared with adipocytes treated with scrambled siRNA.
However, the decrease of TBC1D4 had no significant effect
on either GLUT1 or GLUT4 protein levels. To discriminate
between effects of siRNA-mediated suppression of TBC1D1 on
transcription versus translation of GLUT1, we measured GLUT1
mRNA levels using real-time PCR. As shown in Figure 3(C),
silencing of TBC1D1 did not change GLUT1 and GLUT4 mRNA
levels significantly. These data suggest that TBC1D1 suppresses
GLUT1 expression mainly at the post-transcriptional level.
TBC1D1 is a negative regulator of the mTOR/p70 S6 kinase pathway
We next investigated whether TBC1D1 is involved in the
regulation of insulin signalling on the protein synthesis
pathway. As shown in Figures 4(A) and 4(B), siRNA-induced
knockdown of either TBC1D1 or TBC1D4 had no effect
on basal or insulin-stimulated phosphorylation of Akt (Ser473)
in adipocytes. Quantitatively, suppression of TBC1D1 slightly
increased basal ERK (extracellular-signal-regulated kinase) 1/2
phosphorylation, but did not significantly alter insulin-stimulated
ERK phosphorylation. Interestingly, suppression of TBC1D1, but
not TBC1D4, significantly increased basal phosphorylation of p70
S6 kinase at Thr389, a phosphorylation site induced by activated
mTOR. Increased phosphorylation at Thr389 in p70 S6 kinase can
lead to its activation [46–48]. Consistent with the increase of p70
S6 kinase activity, we also observed that suppression of TBC1D1
resulted in the increase in phosphorylation of S6 ribosomal protein
at Ser235/236, the sites phosphorylated by activated p70 S6 kinase,
although the protein levels of S6 ribosomal protein were not
altered (Figure 4A, bottom panel). These results strongly suggest
that siRNA-induced silencing of TBC1D1 increases the activity
of the mTOR pathway. However, the decrease of TBC1D1 did
not alter insulin-stimulated phosphorylation of p70 S6 kinase and
S6 ribosomal protein (Figures 4A and 4B). In our hands, the
effect of TBC1D1 silencing on the mTOR pathway is similar
to that observed in adipocytes lacking TSC2 (data not shown),
a known Akt substrate and negative regulator of the mTOR
pathway. Our data are consistent with the notion that TBC1D1 is
a negative regulator of the mTOR/p70 S6 kinase pathway in 3T3-
L1 adipocytes. It is possible that insulin signalling phosphorylates
and inactivates TBC1D1, leading to activation of the mTOR
pathway. Therefore, knockdown of TBC1D1 may mimic insulin’s
effect, resulting in the increase of basal phosphorylation of p70
S6 kinase and S6 ribosomal protein without altering insulin’s
stimulatory effects.
Inhibition of mTOR prevents upregulation of GLUT1 protein
expression induced by loss of TBC1D1
It has been reported that insulin stimulates GLUT1 expression
through the mTOR signalling pathway, since inhibition of mTOR
c© The Authors Journal compilation c© 2008 Biochemical Society
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Figure 2 Gene silencing of TBC1D1, but not TBC1D4 or RapGAP220, increases glucose transport in 3T3-L1 adipocytes
3T3-L1 adipocytes were transfected with the indicated siRNAs (10 nmol) by electroporation and reseeded and incubated for 72 h. Scr, scrambled. (A) Comparison of insulin-stimulated [3H]deoxyglucose
uptake by adipocytes transfected with different siRNAs. The serum-starved cells were stimulated by 1 or 100 nM insulin and the deoxyglucose uptake was assayed as described in the Experimental
section. (B, C and E) siRNA-induced gene silencing. Total RNA was extracted from cells transfected with siRNAs as indicated using TRIZOL reagent. Agarose gel images of RT–PCR and real-time
PCR results show TBC1D1 (B and C) and RapGAP220 (E) mRNA knockdowns. (D) Western blot shows TBC1D4 protein knockdown by siRNA. Cell lysates were prepared and 30 µg of protein from
each sample was resolved by SDS/PAGE and immunoblotted with anti-TBC1D4 antibody. Data are presented as the mean +− S.E.M. of five independent experiments and the unpaired Student’s t test
showed *P < 0.05 and **P < 0.005 for differences between cells transfected with scrambled siRNA against cells transfected with siRNAs as indicated.
with rapamycin completely blocks the insulin effect [57,58]. As
described above, we observed that suppression of TBC1D1 leads
to both the activation of the mTOR pathway and an increase of
GLUT1 protein. Therefore, we tested whether mTOR activity
is required for the increase in the GLUT1 protein level in the
adipocytes lacking TBC1D1. As shown in Figures 5(A) and
5(C), inhibition of mTOR activity with rapamycin for 8 h did
not significantly alter the elevated GLUT1 protein expression
induced by the silencing of TBC1D1 (Figure 5B), although
phosphorylation of S6 ribosomal protein in the total cell lysate
was completed blocked (Figure 5A, second panel). However,
treatment of the cells with rapamycin for the last 48 h of the
72 h gene-silencing protocol completely prevented this increase
of GLUT1 protein in the cells transfected with TBC1D1 siRNA.
The lack of effect of rapamycin over only the last 8 h is not
unexpected, given the longer half-life of the GLUT1 protein.
As expected, short-term treatment (4 h) with insulin did not
significantly change GLUT1 protein levels in the cells transfected
with either scrambled or TBC1D1-specific siRNAs.
Overexpression of mutant TBC1D1-T590A blocks insulin-stimulated
phosphorylation of p70 S6 kinase
Further studies were designed to test whether a TBC1D1-T590A
mutant lacking the Akt phosphorylation site affects insulin-
stimulated activation of mTOR. Since the DNA transfection
efficacy is much higher in CHO-T cells (Chinese hamster ovary
cells transfected with the human insulin receptor) (∼50%)
than in 3T3-L1 adipocytes (<5%), CHO-T cells were used in
these experiments. In this protocol, pCMV5 vectors with DNA
inserts coding HA-tagged TBC1D4, Myc-tagged TBC1D1-WT or
Myc-tagged TBC1D1-T590A were transfected into CHO-T cells
by electroporation. Then, 48 h later, serum-starved cells were
stimulated with insulin (10 nM) for 20 min before total lysate
c© The Authors Journal compilation c© 2008 Biochemical Society
652 Q. L. Zhou and others
Figure 3 Gene silencing of TBC1D1 enhances GLUT1 protein but not gene
expression in 3T3-L1 adipocytes
3T3-L1 adipocytes were transfected with the indicated siRNA (10 nmol) by electroporation,
reseeded and incubated for 72 h. (A) Cell lysates were prepared and 30 µg of protein from
each sample was resolved by SDS/PAGE and immunoblotted with anti-GLUT1, anti-GLUT4,
anti-TBC1D4 and anti-Akt antibodies. (B) Protein bands of GLUT1 expression were scanned
and intensities were determined by densitometry using the Adobe Photoshop CS2 software
program. (C) Total RNA was extracted from cells transfected with the indicated siRNAs using
TRIZOL reagent and real-time PCR results show mRNA levels of GLUT1 and GLUT4. Data are
presented as the mean +− S.E.M. of three independent experiments and *P < 0.005 as compared
with the scrambled (Scr) siRNA group.
was prepared for detection of insulin-stimulated phosphorylation
of Akt/PKB (Ser473) and p70 S6 kinase (Thr389), as well as the
expression of HA-tagged TBC1D4 and Myc-tagged TBC1D1
(Figures 6A and 6B). Quantification of the Western blot analyses
revealed that overexpression of TBC1D1-T590A significantly
reduced insulin-stimulated phosphorylation of p70 S6 kinase at
Thr389, but not phosphorylation of Akt/PKB at Ser473, as compared
with the cells expressing TBC1D4 or WT TBC1D1. It is possible
that WT TBC1D1 can be phosphorylated and inhibited by insulin
so that it cannot prevent insulin-induced activation of the mTOR
pathway. However, the Akt phosphorylation site mutant TBC1D1-
T590A cannot be phosphorylated and inhibited by activated
Akt in insulin-stimulated cells. Therefore, overexpression of the
mutant form of TBC1D1 will partially block insulin’s effect on
phosphorylation of p70 S6 kinase. These data are consistent with
the notion that TBC1D1 is a negative regulator of the mTOR
pathway and that Akt-induced phosphorylation of the Thr590
residue may result in the inactivation of the GAP domain-contain-
ing protein and, at least partly, the activation of the mTOR/p70
S6 kinase pathway.
Figure 4 Gene silencing of TBC1D1 activates the mTOR/p70 S6 kinase
pathway in 3T3-L1 adipocytes
3T3-L1 adipocytes were transfected with indicated siRNA (10 nmol) by electroporation, reseeded
and incubated for 72 h. The cells were serum starved for 5 h, followed by treatment with or without
insulin (100 nM) for 20 min. Total cell lysates were prepared and 15–30 µg of protein from
each sample was resolved by SDS/PAGE and immunoblotted with the antibodies as indicated
(A) and protein bands of phospho-p70 S6 kinase (P-p70S6K), phospho-S6 ribosomal protein
(P-S6RP), phospho-Akt (P-Akt) and phospho-Erk2 (P-Erk2) were scanned and intensities were
determined by densitometry using the Adobe Photoshop CS2 software program (B). Levels of
S6 ribosomal protein (S6RP) are shown as control. Data are presented as the mean +− S.E.M.
of four independent experiments and *P < 0.005 and #P < 0.005 as compared with the
scrambled (Scr) siRNA groups.
DISCUSSION
Using both mass spectrometry-based proteomics with PAS
antibody and Akt phosphorylation motif-based bioinformatics
to isolate putative Akt substrate proteins, we could confirm
that several GAPs are potential Akt/PKB substrates in insulin-
stimulated 3T3-L1 adipocytes. These include the known Akt/PKB
substrates TSC2 [28,29,40], TBC1D4 [30], and RapGAP220
[33]. We also identified a novel GAP domain-containing protein,
TBC1D1, as a novel Akt/PKB substrate by showing that the
expressed protein directly reacts with PAS antibody after insulin
stimulation (Figure 1). A point mutation of the putative Akt
phosphorylation site revealed that Rab GAP TBC1D1 is indeed
phosphorylated in response to insulin at Thr590, as predicted by the
Scansite motif search program [8]. A key finding in the present
study is that silencing of the RabGAP TBC1D1 increases basal
deoxyglucose transport in 3T3-L1 adipocytes (Figure 2). This
increase is also observed in the presence of submaximal doses
of insulin, but not when maximal concentrations of insulin are
present (Figure 2). Loss of TBC1D1 also significantly increases
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Figure 5 Inhibition of mTOR prevents the increase in GLUT1 protein
expression due to the decrease of TBC1D1 in 3T3-L1 adipocytes
3T3-L1 adipocytes were transfected with indicated siRNA (10 nmol) by electroporation, reseeded
and incubated for 72 h. (A) The cells were then treated with or without 20 nM rapamycin (Rap)
for 8 h or 48 h, then with or without 100 nM insulin (Ins) for 4 h. Total cell lysates were prepared
and 20 µg of protein from each sample was resolved by SDS/PAGE and immunoblotted with
antibodies as indicated. P-S6RP, phospho-S6 ribosomal protein. (B) Agarose gel images show
the results of the PCR analysis of TBC1D1 and TBC1D4 mRNA knockdowns. (C) Protein bands
of GLUT1 expression were scanned and intensities were determined by densitometry using the
Adobe Photoshop CS2 software program. Data are presented as the mean +− S.E.M. of three
independent experiments and *P < 0.005 as compared with the scrambled (Scr) siRNA groups.
the expression of GLUT1 protein, but not GLUT4 protein,
in the cultured adipocytes, suggesting that the upregulation of
GLUT1 protein expression probably contributes to the increase in
deoxyglucose transport (Figure 3). The data are consistent with
the concept that GLUT1 accounts for most of the glucose uptake
in unstimulated cells, whereas GLUT4 contributes more to the
insulin-stimulated glucose uptake. It is interesting to note that,
while we were preparing for this manuscript, a study published
recently suggested that TBC1D1 acts similarly to TBC1D4
(AS160) as a negative regulator of insulin-stimulated GLUT4
translocation in 3T3-L1 adipocytes [59]. However, our data also
demonstrated that cells with a double knockdown of TBC1D1
and GLUT4 still showed increased basal glucose transport as
compared with cells treated with the scrambled and GLUT4
siRNAs together (results not shown). Taken together, our data
suggest that the increase of basal glucose transport by siRNA-
induced suppression of TBC1D1 is dependent on GLUT1 but not
GLUT4.
In the present study, our data also showed that insulin stimulates
TBC1D4 (AS160) phosphorylation in adipocytes, as detected by
Figure 6 Mutation of TBC1D1 at the Akt phosphorylation site inhibits the
activation of the mTOR-p70 S6 kinase pathway in CHO-T cells
CHO-T cells were transfected with Myc-tagged TBC1D1-WT, Myc-tagged TBC1D1-T590A and
HA-tagged TBC1D4-WT by electroporation, reseeded and incubated for 48 h. The cells were
then treated with or without insulin (Ins; 10 nM) for 30 min. (A) Total cell lysates were prepared
and 30 µg of protein from each sample was resolved by SDS/PAGE and immunoblotted with
antibodies as indicated. P-Akt, phospho-Akt; P-p70S6K, phospho-p70 S6 kinase. (B) Protein
bands of phospho-p70 S6 kinase were scanned and intensities were determined by densitometry
using the Adobe Photoshop CS2 software program. Data are presented as the mean +− S.E.M.
of three independent experiments and *P < 0.005 as compared with the TBC1D4 WT group.
the PAS antibody, confirming previously reported data [30]. To
our surprise, suppression of TBC1D4 did not alter either basal
or insulin-stimulated deoxyglucose transport, even though about
80% loss of TBC1D4 protein was detected in the cells treated
with the TBC1D4 gene-specific siRNA (Figure 2). The effect of
silencing of TBC1D4 on glucose transport was repeated more
than ten times with different batches of cells and siRNAs. One
possible explanation is that the remaining 20% of the RabGAP
TBC1D4 or TBC1D1 is enough to function fully as a negative
regulator of GLUT4 translocation and glucose transport. Studies
correlating levels of expression of shRNA (short hairpin RNA)
against this protein are consistent with this idea since only the cells
showing greatest knockdown displayed compromised GLUT4
translocation [20]. Although both TBC1D1 and TBC1D4 are
Akt substrates in insulin-stimulated adipocytes, our study for the
first time provides evidence suggesting that TBC1D1, but not
its isoform TBC1D4, is involved in the negative regulation of
GLUT1 protein expression and basal glucose transport activity
in adipocytes. It is worth noting that both TBC1D1 and TBC1D4
contain two PTB domains, suggesting that they may be potentially
involved in the interaction with other phosphoproteins and
different cellular functions, such as regulating GLUT1 expression
by TBC1D1, as described in the present study, and phagosomal
maturation by the TBC1D4–Rab14 pathway, reported recently
[60]. Interestingly, it was reported that insulin and AMPK (AMP-
activated protein kinase) activators regulate both TBC1D1 and
TBC1D4 phosphorylation and that they interact with adaptor
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protein 14-3-3 differently in cultured L6 myotubes, These data
suggest potentially distinct intracellular targeting mechanisms for
these GAP domain-containing proteins [61].
Activation of the PI3K pathway by insulin and growth factors
leads to Akt/PKB-mediated phosphorylation and inactivation of
TSC2 [28,29,40]. Since TSC2 is a GAP for the small GTPase
Rheb [37–39], inhibition of TSC2 by Akt/PKB leads to the
activation of Rheb. Rheb in turn forms a complex with Raptor
and activates mTOR by an unknown mechanism [47,48]. Active
mTOR regulates protein synthesis through phosphorylation
of p70 S6 kinase and the translation regulator 4E-BP1. It
has been reported that insulin stimulates glucose transporter
GLUT1 protein translation through the mTOR pathway since the
mTOR specific inhibitor rapamycin prevents this insulin effect
[57,58]. Interestingly, in the present study we also observed
that the Rab GAP TBC1D1, a novel Akt/PKB substrate, is a
negative regulator of GLUT1 protein expression. In addition,
RNAi-induced knockdown of endogenous TBC1D1 increases
phosphorylation of p70 S6 kinase at Thr389, a known mTOR phos-
phorylation site (Figure 4). Loss of TBC1D1 also increases
phosphorylation of the p70 S6 kinase substrate S6 ribosomal pro-
tein (Figure 4). In contrast, overexpression of the TBC1D1-
T590A mutant inhibits insulin-stimulated phosphorylation of p70
S6 kinase at Thr389 (Figure 6). Taken together, our data suggest
that TBC1D1, similar to TSC2, is a novel negative regulator of
the mTOR pathway. Furthermore, TBC1D1 negatively regulates
GLUT1 protein expression through inhibiting the mTOR pathway
since inhibition of mTOR with rapamycin blocks the stimulatory
effect of TBC1D1 knockdown on GLUT1 protein (Figure 5).
These results suggest a new pathway by which Akt mediates
glucose transport activity in cultured adipocytes. It will be
interesting in future studies to elucidate the molecular mechanism
by which TBC1D1 regulates the activity of mTOR.
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